Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half ...

which has an easy auto-injector mechanism. “These marketing authorisations constitute significant milestones for Novo Nordisk and the treatment of diabetes. We look forward to making Tresiba and ...

Both new doses can be bought for $499 for a month's supply via the company's LillyDirect direct-to-consumer self-pay channel, $150 lower than it charges for the injector pen formulations of those ...

The plant will produce next generation steel that will be used by Hyundai’s two US auto plants ... value from Novo’s share price as investors’ hopes of finding a superior alternative to the company’s ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

Novo Nordisk (NVO) announced updates to the Wegovy savings program, allowing all eligible cash-paying patients access to Wegovy injection 0.25 ...

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...